Calculus bovis sativus
PreclinicalSmall molecule
Calculus bovis sativus is one of 101 small molecule programs targeting Intracerebral Hemorrhage. It is currently in Preclinical.
5
Indications
5
Total Trials
5
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
228 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Rinvoq
AbbViePhase 3
Savaysa
Daiichi SankyoPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Rilutek
AAzurity Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
BESREMI
PPharmaEssentia
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Apatinib Mesylate
BBukwang Pharmaceutical
Phase 3
Becotatug Vedotin
FFudan University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Encephalitis1 trial
Intracerebral Hemorrhage1 trial
Inflammatory Demyelinating Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Calculus bovis sativus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- TTongji Hospital